DementiaABCVNCT06245499
Aging Brain Care Virtual Program
A study testing Aging Brain Care Virtual Program in people with Dementia and Alzheimer Disease, run by Indiana University at 1 site in United States.
Trial summary
The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Dementia, Alzheimer Disease
- What is being tested?
- Aging Brain Care Virtual Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 987 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Mar 2024to 31 Oct 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Patient Inclusion Criteria:
- 65 and older,
- active primary care patient (visit in past 14 months),
- diagnosis of Alzheimer's disease and related dementias (ADRD) based on ICD criteria in primary care problems list.
Patient Exclusion Criteria:
- enrolled in hospice at the study start (study screening)or
- living in a long term care nursing facility.
Care Partners Inclusion Criteria:
- 18 and older,
- able to access a phone or computer for intervention delivery in English, and
- identified in the EMR as the emergency contact or as the primary care partner.
Care Partners Exclusion Criteria:
- Individuals who decline to participate in the ABCV intervention
Trial locations and contacts
1 site in 1 country.
United States1 site
Regenstrief Institute, Inc.
Indianapolis, Indiana, 46202
About this study
Official title: The Aging Brain Care Virtual Program
The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
- Conditions
- Dementia, Alzheimer Disease
- Being tested
- Aging Brain Care Virtual Program
- Keywords
- Telehealth, Virtual intervention, Aging brain care
- Medical subject headings
- Dementia, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Aging Brain Care Virtual ProgramBehavioural
Also called ABCV
The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Care Partners in the intervention group will be approached and offered care coordination through the Aging Brain Care Virtual program Receives: Behavioral: Aging Brain Care Virtual Program |
| Control | No intervention | Care partners in the control group will not be approached, but outcomes data will be collected from the EMR for comparison with the intervention group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Emergency Department Utilization
Total count of emergency department encounters per patient.
Measured: During the 12 months of intervention
Secondary outcomes (5)
New Prescriptions for Benzodiazepine and/or Antipsychotic Medications
Total count of new prescriptions for benzodiazepine and/or antipsychotic medications per patient.
Measured: During the 12 months of intervention
Change in Anticholinergic Cognitive Burden Scale Score
The Anticholinergic Cognitive Burden Scale (ACB) provides a total score rating the anticholinergic burden of medications the patient is taking. There are 88 medications on the Anticholinergic Cognitive Burden Scale.
Possible anticholinergics include those listed with a score of 1; Definite anticholinergics include those listed with a score of 2 or 3.
The overall ACB score is calculated by adding the score for each possible or definite anticholinergic medication that the patient is taking.
An ACB score can be as low as 0. The vast majority of patients have an ACB score at or below 4. Scores of 1 are low, 2 are moderate and anything above 3 is considered high. There is no published max score on the ACB scale, however, scores above 4 are somewhat uncommon. The top score could be as high as 264 (88x3)
A higher ACB score indicates higher cognitive burden. Higher scores indicate worse outcomes.
Measured: Before and 12 months after initial intervention
Acceptability of the Intervention Score
Acceptability of Intervention Measure (AIM) Scores range from 4 to 20. Cut-off scores for interpretation are not yet available however higher scores indicate superior psychometric quality.
Measured: During the 12 month intervention period
Feasibility of the Intervention Score
Feasibility of Intervention Measure (FIM) Scores range from 4 to 20. Cut-off scores for interpretation are not yet available however higher scores indicate superior psychometric quality.
Measured: During the 12 month intervention period
Appropriateness of the Intervention Score
Intervention Appropriateness Measure (IAM) Scores range from 4 to 20. Cut-off scores for interpretation are not yet available however higher scores indicate superior psychometric quality.
Measured: During the 12 month intervention period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Feb 2024
- Study start11 Mar 2024
- Primary completion31 Oct 2025
- Study completion31 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 987 participants (actual)
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA), Regenstrief Institute, Inc., Indiana University Health
- Responsible party
- Principal investigator, Alexia M. Torke, Indiana University
- Investigators
- Alexia M Torke, MD, MS, Principal investigator, Regenstrief Institute, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06245499
- Sponsor's protocol ID
- FY23_Demo2_Torke
- Other IDs
- 20249, U54AG063546
- Acronym
- ABCV
- Status last verified
- Sep 2026
- First submitted
- 30 Jan 2024
- Last updated
- 10 Sep 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sauerteig-Rolston MR, Fowler NR, Sachs GA, Boustani M, Slaven J, Monahan PO, Burke ES, Higbie A, Torke AM. Pragmatic trial of a virtual dementia collaborative care management program: protocol for the Aging Brain Care Virtual (ABCV) program. BMJ Open. 2025 Sep 23;15(9):e108800. doi: 10.1136/bmjopen-2025-108800.
PubMed 40987722
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Aging Brain Care Virtual Program
- ClinicalTrials.gov ID
- NCT06245499
- Acronym / sponsor ID
- ABCV / FY23_Demo2_Torke
- Conditions
- Dementia, Alzheimer Disease
- Keywords
- Telehealth, Virtual intervention, Aging brain care
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 987 participants (actual)
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA), Regenstrief Institute, Inc., Indiana University Health
- Study start
- 11 Mar 2024 (actual)
- Primary completion
- 31 Oct 2025 (actual)
- Study completion
- 31 Oct 2025 (actual)
- First posted
- 7 Feb 2024 (actual)
- Results
- Posted 10 Sep 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: Aging Brain Care Virtual ProgramCare Partners in the intervention group will be approached and offered care coordination through the Aging Brain Care Virtual program |
| Control | No intervention | –Care partners in the control group will not be approached, but outcomes data will be collected from the EMR for comparison with the intervention group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Aging Brain Care Virtual ProgramAlso: ABCVThe program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning. | Behavioural | Intervention |
Primary outcome
Emergency Department Utilization
Time frame: During the 12 months of intervention
Total count of emergency department encounters per patient.
5 secondary outcomes
New Prescriptions for Benzodiazepine and/or Antipsychotic Medications
Time frame: During the 12 months of intervention
Change in Anticholinergic Cognitive Burden Scale Score
Time frame: Before and 12 months after initial intervention
Acceptability of the Intervention Score
Time frame: During the 12 month intervention period
Feasibility of the Intervention Score
Time frame: During the 12 month intervention period
Appropriateness of the Intervention Score
Time frame: During the 12 month intervention period
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40987722Sauerteig-Rolston MR, Fowler NR, Sachs GA, Boustani M, Slaven J, Monahan PO, Burke ES, Higbie A, Torke AM. Pragmatic trial of a virtual dementia collaborative care management program: protocol for the Aging Brain Care Virtual (ABCV) program. BMJ Open. 2025 Sep 23;15(9):e108800. doi: 10.1136/bmjopen-2025-108800.
- Individual participant dataSharing planned: No
Related trials for Dementia
Not yet recruiting
Virtual Reality to Advance Dementia Care and Quality of Life
Dementia, Agitation
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
Not yet recruiting
A Hybrid Effectiveness-Implementation and Cost-Utility Evaluation of a Support Programme for Informal Carers of People With Dementia in Primary Care (EsCuidar2)
Quality of Life
Recruiting
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
Obstructive Sleep Apnea, Cognitive Decline
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexia M Torke, MD, MS principal investigator
Regenstrief Institute, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aging Brain Care Virtual Program in people with Dementia and Alzheimer Disease, run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Sep 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Emergency Department Utilization (time frame: During the 12 months of intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06245499, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.